NO20053467L - Fremgangsmate ved biotransformasjon av kolkionforbindelser til de tilsvarende 3-glykosyl-derivater - Google Patents

Fremgangsmate ved biotransformasjon av kolkionforbindelser til de tilsvarende 3-glykosyl-derivater

Info

Publication number
NO20053467L
NO20053467L NO20053467A NO20053467A NO20053467L NO 20053467 L NO20053467 L NO 20053467L NO 20053467 A NO20053467 A NO 20053467A NO 20053467 A NO20053467 A NO 20053467A NO 20053467 L NO20053467 L NO 20053467L
Authority
NO
Norway
Prior art keywords
biotransformation
pharmaceutically acceptable
glycosyl derivatives
pharmaceutical
carbonic compounds
Prior art date
Application number
NO20053467A
Other languages
English (en)
Norwegian (no)
Inventor
Tsuyoshi Naganuma
Mitsuo Muramatsu
Original Assignee
Kissei Pharmaceutical Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32588229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20053467(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical Company filed Critical Kissei Pharmaceutical Company
Publication of NO20053467L publication Critical patent/NO20053467L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20053467A 2002-12-16 2005-07-15 Fremgangsmate ved biotransformasjon av kolkionforbindelser til de tilsvarende 3-glykosyl-derivater NO20053467L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002364238 2002-12-16
PCT/JP2003/015837 WO2004054574A1 (ja) 2002-12-16 2003-12-11 経口固形医薬

Publications (1)

Publication Number Publication Date
NO20053467L true NO20053467L (no) 2005-07-15

Family

ID=32588229

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053467A NO20053467L (no) 2002-12-16 2005-07-15 Fremgangsmate ved biotransformasjon av kolkionforbindelser til de tilsvarende 3-glykosyl-derivater

Country Status (24)

Country Link
US (2) US20060018959A1 (pl)
EP (2) EP2402010A1 (pl)
JP (1) JP4633469B2 (pl)
KR (2) KR101077061B1 (pl)
CN (2) CN101069685B (pl)
AU (1) AU2003289320C1 (pl)
BR (1) BR0317349A (pl)
CA (1) CA2507002C (pl)
EA (1) EA008196B1 (pl)
ES (1) ES2544560T3 (pl)
HK (2) HK1107768A1 (pl)
HR (1) HRP20050544B1 (pl)
IL (1) IL169040A (pl)
IS (1) IS7929A (pl)
ME (2) MEP10808A (pl)
MX (1) MXPA05006513A (pl)
NO (1) NO20053467L (pl)
NZ (1) NZ540664A (pl)
PL (1) PL220457B1 (pl)
RS (1) RS58025B1 (pl)
TW (2) TWI325318B (pl)
UA (2) UA84694C2 (pl)
WO (1) WO2004054574A1 (pl)
ZA (1) ZA200504613B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2557758C (en) * 2004-03-05 2013-09-10 Kissei Pharmaceutical Co., Ltd. Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder
WO2006038611A1 (ja) * 2004-10-05 2006-04-13 Kissei Pharmaceutical Co., Ltd. 下部尿路閉塞疾患に伴う蓄尿障害の予防及び／又は治療剤
MX2009009230A (es) * 2007-02-28 2009-11-26 Kissei Pharmaceutical Uso de silodosina en una administracion diaria para tratar hiperplasia prostatica benigna.
CL2008000727A1 (es) * 2007-03-13 2008-10-17 Takeda Pharmaceutical Granulo compuesto por 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluorobenzonitrilo o una de sus sales y un aditivo que no comprende celulosa microcristalina; preparacion solida; comprimido y procedimi
JP5965902B2 (ja) 2010-06-28 2016-08-10 ラティオファルム ゲー・エム・ベー・ハー シロドシン−シクロデキストリン包接化合物
EP2595607A2 (de) 2010-07-23 2013-05-29 Ratiopharm GmbH Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer
SI2474529T1 (sl) 2010-12-23 2014-12-31 Sandoz Ag Kristalne oblike aktivne farmacevtske učinkovine
CN102283816B (zh) * 2011-08-05 2013-09-11 北京海步国际医药科技发展有限公司 西洛多辛缓释片剂及其制备方法
US20140243383A1 (en) * 2011-08-24 2014-08-28 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
JP6031722B2 (ja) * 2011-08-31 2016-11-24 国立大学法人 千葉大学 女性の排尿障害の治療剤
EP2744498A4 (en) * 2012-02-16 2014-12-03 Teva Pharma N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF
EP2872488B1 (en) 2012-07-16 2018-08-22 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US20160045446A1 (en) 2013-03-26 2016-02-18 Kissei Pharmaceutical Co., Ltd. Oral administration preparation with masked bitterness of silodosin
EP3708154A1 (en) 2013-06-06 2020-09-16 Fibrogen, Inc. Pharmaceutical formulations of a hif hydroxylase inhibitor
KR102206104B1 (ko) 2014-04-03 2021-01-22 한미약품 주식회사 실로도신을 포함하는 과립물, 및 이를 포함하는 약학적 조성물 및 제형
CN103933001A (zh) * 2014-05-09 2014-07-23 浙江华海药业股份有限公司 一种稳定的赛洛多辛口服固体药物组合物及其制备方法
CN105435233B (zh) * 2014-08-06 2018-05-01 江苏正大丰海制药有限公司 一种英加韦林的药物组合物
JP6366547B2 (ja) * 2015-08-03 2018-08-01 大原薬品工業株式会社 光安定性が向上した、プラミペキソール製剤包装体
CN108685867A (zh) * 2017-04-06 2018-10-23 昆明积大制药股份有限公司 一种赛洛多辛薄膜衣片及其制备方法
EP3354283B1 (en) 2017-06-20 2019-08-07 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical capsule composition comprising silodosin
CN111437260A (zh) * 2019-01-17 2020-07-24 北京万全德众医药生物技术有限公司 用于制备盐酸美金刚固态药物组合物的方法
JP7262005B2 (ja) * 2019-01-25 2023-04-21 日本ジェネリック株式会社 シロドシン含有固形組成物及びその製造法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060073A (en) 1963-03-02 1967-02-22 Benger Lab Ltd 2,2,2-trichlorethyl hydrogen succinate and salts
US4547498A (en) 1983-01-06 1985-10-15 Mylan Pharmaceuticals Inc. Pharmaceutical combination composition and associated method
US4757090A (en) * 1986-07-14 1988-07-12 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
HU200926B (en) * 1988-10-28 1990-09-28 Egyt Gyogyszervegyeszeti Gyar Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules
EP0600675B1 (en) 1992-12-02 1998-07-08 Kissei Pharmaceutical Co., Ltd. Indoline compounds for the treatment of dysuria
US5370878A (en) * 1993-09-30 1994-12-06 Hallmark Pharmaceuticals, Inc. Method for preparing a direct compression granulated acetaminophen composition
ES2163504T5 (es) 1994-05-06 2008-05-16 Pfizer Inc. Formas de dosificacion de liberacion controlada de azitromicina.
ES2125198B1 (es) * 1997-05-13 1999-11-16 Vita Invest Sa Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
AU9095998A (en) * 1997-09-22 1999-04-12 Kissei Pharmaceutical Co. Ltd. Remedies for dysuria resulting from prostatic hypertrophy
US20020177593A1 (en) * 1998-09-30 2002-11-28 Yuji Ishihara Agents and crystals for improving excretory potency of urinary bladder
JP4324266B2 (ja) 1999-02-26 2009-09-02 キッセイ薬品工業株式会社 α１Ａアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤
US20010053780A1 (en) 1999-04-30 2001-12-20 Whitaker John S. Daily treatment for erectile dysfunction using a PDE5 inhibitor
JP4014068B2 (ja) * 1999-07-28 2007-11-28 芦森工業株式会社 エアバッグ装置
PE20011178A1 (es) * 2000-04-07 2001-11-19 Takeda Chemical Industries Ltd Compuestos heterociclicos y su produccion
EP1293206A4 (en) 2000-05-15 2005-09-21 Kissei Pharmaceutical LIQUID PREPARATION BASED ON WATER
KR100596257B1 (ko) * 2001-01-26 2006-07-03 쉐링 코포레이션 스테롤 흡수 억제제를 포함하는 조성물, 및 페록시솜 증식인자-활성화 수용체 활성화제와 스테롤 흡수 억제제를 포함하는 조성물 및 조합물
JP2001288115A (ja) 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
KR20030076715A (ko) * 2001-03-01 2003-09-26 그레랑 파마수티컬 가부시키가이샤 페노피브라이트 함유 조성물
US6786714B2 (en) * 2001-04-12 2004-09-07 James W. Haskew Delivery system for liquid catalysts
GB0113843D0 (en) 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
UA78854C2 (en) * 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same

Also Published As

Publication number Publication date
MXPA05006513A (es) 2005-09-08
PL377495A1 (pl) 2006-02-06
CN101069685B (zh) 2011-12-14
UA84694C2 (ru) 2008-11-25
IL169040A (en) 2013-04-30
EA008196B1 (ru) 2007-04-27
HRP20050544A2 (en) 2006-09-30
RS20050470A (en) 2007-09-21
TWI382838B (zh) 2013-01-21
UA85359C2 (ru) 2009-01-12
US20120064154A1 (en) 2012-03-15
KR101072909B1 (ko) 2011-10-17
IS7929A (is) 2005-07-01
CN100339078C (zh) 2007-09-26
CA2507002C (en) 2012-09-18
EP2402010A1 (en) 2012-01-04
NZ540664A (en) 2007-09-28
TWI325318B (en) 2010-06-01
TW200944200A (en) 2009-11-01
RS58025B1 (sr) 2019-02-28
AU2003289320A1 (en) 2004-07-09
TW200418457A (en) 2004-10-01
AU2003289320B2 (en) 2008-08-21
HK1085131A1 (en) 2006-08-18
EP1574215A1 (en) 2005-09-14
CN101069685A (zh) 2007-11-14
JP4633469B2 (ja) 2011-02-16
ME00076B (me) 2011-02-10
KR20050084316A (ko) 2005-08-26
US20060018959A1 (en) 2006-01-26
HRP20050544B1 (hr) 2017-12-01
CA2507002A1 (en) 2004-07-01
MEP10808A (en) 2010-06-10
CN1726028A (zh) 2006-01-25
JPWO2004054574A1 (ja) 2006-04-20
EA200500985A1 (ru) 2005-12-29
PL220457B1 (pl) 2015-10-30
EP1574215A4 (en) 2009-07-01
BR0317349A (pt) 2005-11-16
HK1107768A1 (en) 2008-04-18
KR20100133024A (ko) 2010-12-20
ZA200504613B (en) 2006-08-30
KR101077061B1 (ko) 2011-10-26
EP1574215B1 (en) 2015-07-15
WO2004054574A1 (ja) 2004-07-01
AU2003289320C1 (en) 2018-09-06
ES2544560T3 (es) 2015-09-01

Similar Documents

Publication Publication Date Title
NO20053467L (no) Fremgangsmate ved biotransformasjon av kolkionforbindelser til de tilsvarende 3-glykosyl-derivater
AU2001271741B2 (en) Pharmaceutical compositions of estrogenic agents
CY1121330T1 (el) Συνθεσεις που περιλαμβανουν αζελαστινη και μεθοδοι χρησης αυτων
NO20050397L (no) Tricykliske steroidhormonnukleaere reseptormodulatorer
RU2006109467A (ru) Способы лечения рака с использованием ингибиторов hdac
NO20045072L (no) Tablett med hoyt medikamentinnhold
WO2016179566A1 (en) Methods of treating a neurodegenerative disease
RU2005115855A (ru) Композиция трамадола продлонгированного высвобождением с 24-часовым действием
NO20073465L (no) Benzotiazol-derivater
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
NO20052130L (no) Sterk inhibitor for HCV-serin-protease
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
NO20062004L (no) Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
NO20051901L (no) Nye antimycobakterielle sammensetninger og pyrrole derivater som antimycobakterielle sammensetninger
NO20080697L (no) Modifiserte farmasoytiske doseringsformer for frigivelse av syklooksygenase enzyminhibitor
IS8096A (is) Notkun karbamasepínafleiða til að meðhöndla órósemi í sjúklingum er þjást af vitglöpum
HUT71329A (en) Pharmaceutical compositions for inhibiting cns problems in post-menopausal women containing 2-phenyl-3-aroyl-benzothiophene-derivatives and process for their preparation
NO20050903L (no) Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser
AU2006211205A1 (en) Organic compounds
NO20054360L (no) Nye oxazolderivater, deres fremstilling og anvendelse som farmasotiske preparater
NO20044091L (no) Anvendelse av substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on for fremstilling av medikamenter som inhiberer pankreatisk lipase
HUP0004900A2 (hu) Mozgászavarok kezelésére szolgáló, hatóanyagként NMDA-receptor antagonista hatású piperidinszármazékokat tartalmazó gyógyszerkészítmények
BR112013000164B1 (pt) Agente terapêutico ou agente profilático

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application